Innate Pharma SA Q3 FY2024 earnings call

• Strategy involves leveraging world-class expertise to develop first and best-in-class antibody-based therapies for cancer, with priorities on lead proprietary asset lacutamab, ANKET platform, ADC pipeline, and value-creating partnerships. • Lacutamab is in development for T cell lymphoma, with recent FDA feedback and evaluation of next steps including potential partnership. • ANKET platform has progress with IPH65 in Phase 1 and Sanofi updates on IPH61/SAR’579. • ADC pipeline has IPH45 receiving IND clearance and set to start Phase 1 trials by Q1 next year. • Partnership with AstraZeneca on monalizumab is advancing well in Phase 3 trials for lung cancer.

No detailed financial performance by product segments in absolute terms and revenue contribution % provided in the transcript.

• IPH4502 to start Phase 1 trials by Q1 next year. • Assessing next steps for lacutamab including potential licensing for confirmatory Phase 3 trial in CTCL. • Expecting to complete dose escalation and gather initial safety data for IPH6501 by 2025, with dose optimization and expansion cohorts in non-Hodgkin lymphoma subtypes in later years.

• Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from forecasted.

Q: Could you provide color on lacutamab data to be presented at ASH and regulatory path?

A: Data presentation at ASH is subject to embargo; FDA provided encouraging feedback on proposed regulatory pathway for Sezary syndrome, with alignment needed on confirmatory Phase 3 trial.

Q: Could you confirm need for partner to do confirmatory study for lacutamab and details on finding partner?

A: Working towards confirmatory Phase 3 study, actively seeking partners and exploring other options; guiding principle is to maximize return for Innate.

Q: What's the most likely next step for lacutamab and timelines?

A: Likely to prepare Phase 3 trial, which could be taken up by a partner or funded differently, with timelines to be determined in coming months.

Q: Reason for Sanofi returning IPH67 ANKET?

A: Sanofi did not provide specific reason, as IPH67 was very early-stage; rest of agreement with Sanofi remains in place.

Q: Guidance on timing for ANKET program data update?

A: Expect to complete dose escalation for IPH6501 by 2025, with safety, PK, PD readouts and early efficacy signals, and more clinical efficacy data in 2026.

Q: Target of IPH67 ANKET?

A: Target not currently disclosed.